These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 35355980)

  • 21. TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling.
    Heiniö C; Havunen R; Santos J; de Lint K; Cervera-Carrascon V; Kanerva A; Hemminki A
    Cells; 2020 Mar; 9(4):. PubMed ID: 32225009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.
    Havunen R; Santos JM; Sorsa S; Rantapero T; Lumen D; Siurala M; Airaksinen AJ; Cervera-Carrascon V; Tähtinen S; Kanerva A; Hemminki A
    Mol Ther Oncolytics; 2018 Dec; 11():109-121. PubMed ID: 30569015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer.
    Toivonen R; Suominen E; Grenman R; Savontaus M
    Oncol Rep; 2009 Jan; 21(1):165-71. PubMed ID: 19082458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.
    Xu W; Yang Y; Hu Z; Head M; Mangold KA; Sullivan M; Wang E; Saha P; Gulukota K; Helseth DL; Guise T; Prabhkar BS; Kaul K; Schreiber H; Seth P
    Hum Gene Ther; 2020 Aug; 31(15-16):863-880. PubMed ID: 32394753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma.
    Fang L; Tian W; Zhang C; Wang X; Li W; Zhang Q; Zhang Y; Zheng J
    Pharmacol Res; 2023 Mar; 189():106701. PubMed ID: 36796464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
    Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
    Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.
    Ren Z; Ye X; Fang C; Lu Q; Zhao Y; Liu F; Liang M; Hu F; Chen HZ
    Cancer Biol Ther; 2008 Feb; 7(2):191-95. PubMed ID: 18073525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic adenovirus decreases the proportion of TIM-3
    Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage.
    Pakola S; Quixabeira DCA; Kudling TV; Clubb JHA; Grönberg-Vähä-Koskela S; Basnet S; Jirovec E; Arias V; Haybout L; Heiniö C; Santos JM; Cervera-Carrascon V; Havunen R; Anttila M; Hemminki A
    Front Immunol; 2023; 14():1171083. PubMed ID: 37475863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression.
    Kudling TV; Clubb JHA; Quixabeira DCA; Santos JM; Havunen R; Kononov A; Heiniö C; Cervera-Carrascon V; Pakola S; Basnet S; Grönberg-Vähä-Koskela S; Arias V; Gladwyn-Ng I; Aro K; Bäck L; Räsänen J; Ilonen I; Borenius K; Räsänen M; Hemminki O; Rannikko A; Kanerva A; Tapper J; Hemminki A
    Oncoimmunology; 2022; 11(1):2096572. PubMed ID: 35845722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment.
    Zhang W; Zhang J; Zhang J; Chu J; Zhang Z
    J Nanobiotechnology; 2024 Oct; 22(1):638. PubMed ID: 39420389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer.
    Li D; Duan L; Freimuth P; O'Malley BW
    Clin Cancer Res; 1999 Dec; 5(12):4175-81. PubMed ID: 10632357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response.
    Sadeghirad H; Monkman J; Tan CW; Liu N; Yunis J; Donovan ML; Moradi A; Jhaveri N; Perry C; Adams MN; O'Byrne K; Warkiani ME; Ladwa R; Hughes BGM; Kulasinghe A
    J Transl Med; 2024 Jul; 22(1):677. PubMed ID: 39049036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine.
    Basnet S; Van der Heijden M; Quixabeira DCA; Jirovec E; Grönberg-Vähä-Koskela SAM; Clubb JHA; Kanerva A; Pakola S; Haybout L; Arias V; Hemminki O; Kudling T; Zafar S; Cervera-Carrascon V; Santos JM; Hemminki A
    Mol Ther; 2024 Sep; 32(9):3114-3127. PubMed ID: 38910324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression.
    Cao W; Tian J; Li C; Gao Y; Liu X; Lu J; Wang Y; Wang Z; Svatek RS; Rodriguez R
    Virol J; 2017 Aug; 14(1):149. PubMed ID: 28789701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic effect of Midkine promoter-based conditionally replicating adenoviruses expressing EGFR siRNA in head and neck squamous cancer cell line T891.
    Uehara N; Otsuki N; Kubo M; Kitamoto J; Kojima Y; Teshima M; Shinomiya H; Shirakawa T; Nibu KI
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1231. PubMed ID: 32671980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.
    Siurala M; Havunen R; Saha D; Lumen D; Airaksinen AJ; Tähtinen S; Cervera-Carrascon V; Bramante S; Parviainen S; Vähä-Koskela M; Kanerva A; Hemminki A
    Mol Ther; 2016 Aug; 24(8):1435-43. PubMed ID: 27357626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer.
    Hamada M; Yura Y
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.